Betrosian Alex-P, Agarwal Banwari, Douzinas Emmanuel E
Third Department of Critical Care, Athens University, Evgenidion Hospital, Papadiamantopoulou 20, Athens 11528, Greece.
World J Gastroenterol. 2007 Nov 14;13(42):5552-9. doi: 10.3748/wjg.v13.i42.5552.
Renal dysfunction is common in liver diseases, either as part of multiorgan involvement in acute illness or secondary to advanced liver disease. The presence of renal impairment in both groups is a poor prognostic indicator. Renal failure is often multifactorial and can present as pre-renal or intrinsic renal dysfunction. Obstructive or post renal dysfunction only rarely complicates liver disease. Hepatorenal syndrome (HRS) is a unique form of renal failure associated with advanced liver disease or cirrhosis, and is characterized by functional renal impairment without significant changes in renal histology. Irrespective of the type of renal failure, renal hypoperfusion is the central pathogenetic mechanism, due either to reduced perfusion pressure or increased renal vascular resistance. Volume expansion, avoidance of precipitating factors and treatment of underlying liver disease constitute the mainstay of therapy to prevent and reverse renal impairment. Splanchnic vasoconstrictor agents, such as terlipressin, along with volume expansion, and early placement of transjugular intrahepatic portosystemic shunt (TIPS) may be effective in improving renal function in HRS. Continuous renal replacement therapy (CRRT) and molecular absorbent recirculating system (MARS) in selected patients may be life saving while awaiting liver transplantation.
肾功能障碍在肝脏疾病中很常见,既可以是急性疾病多器官受累的一部分,也可以是晚期肝病的继发表现。两组中出现肾功能损害都是预后不良的指标。肾衰竭往往是多因素导致的,可表现为肾前性或内在性肾功能障碍。梗阻性或肾后性肾功能障碍仅在极少数情况下使肝病复杂化。肝肾综合征(HRS)是一种与晚期肝病或肝硬化相关的独特肾衰竭形式,其特征是功能性肾功能损害而肾脏组织学无明显变化。无论肾衰竭的类型如何,肾灌注不足都是主要的发病机制,这要么是由于灌注压力降低,要么是由于肾血管阻力增加。扩容、避免诱发因素以及治疗潜在的肝病是预防和逆转肾功能损害的主要治疗方法。内脏血管收缩剂,如特利加压素,联合扩容,以及早期放置经颈静脉肝内门体分流术(TIPS)可能有效改善肝肾综合征患者的肾功能。对于部分患者,持续肾脏替代疗法(CRRT)和分子吸附循环系统(MARS)在等待肝移植期间可能挽救生命。